The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $17.10

Today's change0.00 0.00%
Updated March 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $17.10

Today's change0.00 0.00%
Updated March 22 4:00 PM EDT. Delayed by at least 15 minutes.

Ironwood Pharmaceuticals Inc closed at (U.S.)$17.10.

Shares have lost 2.51% over the last five days, but have gained 11.84% over the last year to date. This security has outperformed the S&P 500 by 43.62% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $17.10
  • High--
  • Low--
  • Bid / Ask(U.S.) $11.13 / (U.S.) $200.00K
  • YTD % change+11.84%
  • Volume0
  • Average volume (10-day)1,713,967
  • Average volume (1-month)1,537,330
  • Average volume (3-month)1,411,927
  • 52-week range(U.S.) $9.06 to (U.S.) $18.53
  • Beta1.51
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.56
Updated March 22 4:00 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue87665466
Total other revenue--------
Total revenue87665466
Gross profit86665466
Total cost of revenue2000
Total operating expense94947068
Selling / general / administrative55453736
Research & development38383232
Depreciation / amortization-331--
Interest expense (income), net operating--------
Unusual expense (income)290--
Other operating expenses, total--------
Operating income-6-28-15-2
Interest income (expense), net non-operating-10-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-14-33-22-13
Income after tax-14-33-22-13
Income tax, total--------
Net income-14-33-22-13
Total adjustments to net income--------
Net income before extra. items-14-33-22-13
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-14-33-22-13
Inc. avail. to common incl. extra. items-14-33-22-13
Diluted net income-14-33-22-13
Dilution adjustment--------
Diluted weighted average shares146145145144
Diluted EPS excluding extraordinary itemsvalue per share-0.09-0.23-0.15-0.09
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.08-0.17-0.15-0.09